melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery psychiatric

Hyponeophagia Stress-Induced Anxiety Model
Hyponeophagia – the phenomenon in which exposure to a novel environment suppresses feeding behavior – can be used as an assessment of anxiety in animals. Here at Melior Discovery we have developed a novel environment induced feeding suppression assay (NEIFS) measuring the latency to eat. This test assesses stress-induced anxiety and as such can be used to screen compounds that may have anxiolytic or antidepressant efficacy.

                            

Imipramine, a tricyclic antidepressant, significantly decreases the latency to feed in a novel environment. Data are mean ± SEM; **p<0.01 compared to vehicle.

 

If you are interested in learning more about Novel Environment Feeding Suppression, please contact models@meliordiscovery.com to start the conversation.